LEUKEMIAS

The current landscape for T-cell acute lymphoblastic leukemia has been influenced by 2 key phase 3 trials, Children’s Oncology Group AALL0434 and AALL1231.

Though chimeric antigen receptor T cells are showing promise in T-cell acute lymphoblastic leukemia, challenges, including those related to manufacture, those that are patient/disease specific, and those regarding risk mitigation, remain a struggle.

Utilizing the combination of inotuzuamb ozogamicin and low intensity chemotherapy, with or without blinatumoamab, showed promising results, but also an increase of patient deaths during remission.

Additional data have led to a full FDA approval for blinatumomab.

Promising data were revealed with nelarabine, intensive L-asparaginase, and protracted intrathecal therapy among patients aged 25 years and younger with T-cell acute lymphoblastic leukemia.

Findings from the phase 3 PhALLCON trial show that ponatinib plus reduced-intensity chemotherapy could be a new standard of care for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

In a real-world population of patients with relapsed or refractory B-cell acute lymphoblastic leukemia, modest efficacy was demonstrated with brexucabtagene autoleucel.

Phase 2 FELIX study results show 21.3% of the 94 patients infused with obecatagene autoleucel achieved a complete response or complete response with incomplete count recovery.

The injectable formulation of nelarabine has been granted FDA approval to treatment 2 hematologic malignancies.

The phase 3 PhALLCON trial showed a trend toward event-free survival in patients with Philadelphia chromosome positive acute lymphoblastic leukemia when treated with ponatinib compared with imatinib.

Research shows a high occurrence of ibrutinib-related cardiotoxicity in patients with cancer. This is the first study showing such evidence.

Treatment with tisagenlecleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia led to a 79% morphologic complete response rate.

Phase 2 study shows ponatinib and blinatumomab to represent a promising chemotherapy-free, hematopoietic stem cell transplant–sparing treatment for patients with Philadelphia chromosome–positive acute lymphocytic leukemia.

Treatment with CD19-/CD22-chimeric antigen T-cell therapy demonstrated durable remissions in children with relapsed or refractory B-acute lymphoblastic leukemia, according to a phase 2 study.

An early study showed that encouraging responses were elicited with olverembatinib in patients with ponatinib-resistant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

In the ECOG-ACRIN E1910 study, blinatumomab with consolidation chemotherapy extended overall survival in patients with MRD-negative B-cell acute lymphoblastic leukemia.

Olverembatinib is efficacious and well tolerated in tyrosine kinase inhibitor-resistant CML-CP and CML-AP patients with a BCR-ABL1 T315I mutation.

Based on phase 1 data of the AUGMENT-101 trial, the FDA has granted a breakthrough therapy designation to SNDX-5613 for patients with relapsed or refractory KMT2A rearranged acute leukemia.

Takeda Pharmaceuticals announced that the phase 3 PhALLCON trial of ponatinib for Philadelphia-positive acute lymphoblastic leukemia succeeded in improving the rate of minimal residual disease–negative complete remission.

In an interview with Targeted Oncology, Mark R. Litzow, MD, discussed managing patients with different subtypes of ALL and the session he was a part of during the National Comprehensive Cancer Network 2022 Annual Congress: Hematologic Malignancies.

The FDA has approved a new dosing schedule of Rylaze for patients with acute lymphoblastic leukemia and lymphoblastic lymphoma.

Updated data from the phase 1/2 AUGMENT trial led to a 30% complete remission rate and an overall response rate of 53% with SNDX-5613 when used in patients with relapsed/refractory acute leukemias.

The CAR T-cell therapy tisagenlecleucel showed promising anti-tumor activity in pediatric patients with acute lymphoblastic leukemia.

At the 2022 NCCN: Hematologic Malignancies Conference, a panel discussion gave an overview of current treatment trends for acute myeloid leukemia, as well as supportive care measures to utilize during therapy.

In an interview with Targeted Oncology, Kjeld Schmiegelow, MD provided a deep dive into his SOHO 2022 presentation as well as the other acute lymphoblastic leukemia discussions presented during the session.

Following positive data examining ABC008 for inclusion body myositis, a phase 1/2 trial has begun evaluating the agent in patients with T-cell large granular lymphocytic leukemia.

Experts explain the treatment goals for patients with MDS, and discusses the role of molecular testing in patients with MDS.

Dr Eytan M Stein breaks down how patients with MDS are risk-stratified, and how the clinical outcomes differ between risk groups.

The question of the most optimal therapy for Philadelphia chromosome-positive chronic myeloid leukemia has come down to asciminib vs ponatinib.

Hetty Carraway, MD, describes how MDS differs from acute myeloid leukemia (AML), and the percentage of patients who progress to AML from MDS.